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Abstract
Pancreatic cancer has an abysmal prognosis because
of late diagnosis and lack of effective therapeutics. New
drugs are desperately needed. The present study
determined the effect of the LTB4 receptor antagonist,
LY293111, on tumor growth and metastases in a
fluorescent orthotopic model of pancreatic cancer.
Pancreatic cancer cells (S2-013) with stable expression
of enhanced green fluorescent protein were implanted
into the duodenal pancreatic lobe of athymic mice.
Animals were allocated to four groups (eight mice per
group): control (no treatment); LY293111; gemcitabine;
and LY293111 + gemcitabine. Monitoring of the surgi-
cal procedure and follow-up examinations at 2, 3, and
4weeks after implantation tomonitor tumor growth and
metastases were performed using a fluorescence
microscope and the reversible skin-flap technique. A
staging and scoring system was developed to evaluate
tumor progression, based on the TNM classification.
Control animals developed end-stage disease with
invasive cancer, metastases, and cachexia. Tumor
growth and incidence of metastases were significantly
reduced in all treated mice. However, combined
treatment with LY293111 and gemcitabine was most
effective. LY293111 is a novel therapeutic agent for
pancreatic cancer, which improves the efficacy of
gemcitabine. It is well tolerated and can be adminis-
tered orally and, therefore, provides a new hope for
patients suffering from pancreatic adenocarcinoma.
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Introduction
Patients diagnosed with pancreatic cancer have to face a
disease with an abysmal prognosis and little hope for cure
because effective therapies are not available. Pancreatic
cancer is the fourth leading cause of cancer death in both
men (after lung, prostate, and colon cancers) and women (after
lung, breast, and colon cancers) in the United States, and the
incidence of this disease has not declined. Indeed, it has
increased in Japanese and African Americans over the last
decades [1–3]. Mortality almost equals incidence and most
patients die within 6 months after being diagnosed with this
disease [1,4]. Potentially curative surgery can only be per-
formed in about 20% of these patients because of meta-
static spread or involvement of major blood vessels [4,5].
However, even in this selective group, the 5-year survival rate
is only approximately 20% because of early tumor recurrence
or metastatic tumor progression [6]. Gemcitabine is widely
used as a standard therapy in pancreatic cancer patients in
neoadjuvant, adjuvant, and palliative treatment protocols.
However, besides improving quality of life, survival is only
prolonged for about 1 month [7,8]. Therefore, new therapeutic
strategies are urgently required for pancreatic cancer patients.
[2-Propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]-
propoxy]phenoxy]-benzoic acid (LY293111) is a leukotriene B4
(LTB4) receptor antagonist, which showed marked growth inhibi-
tion of human pancreatic cancer cells in vitro and in subcuta-
neous xenograft models, inducing apoptosis and S-phase
arrest [9]. Recently, it has been shown that LTB4 receptors are
overexpressed in human pancreatic cancer cells and tissues [10].
Moreover, LTB4 stimulates the growth of human pancreatic
cancer cells by inducing ERK1/2 phosphorylation, which can be
inhibited by LY293111 [11,12]. LTB4 is a final product of the
arachidonic acid–metabolizing 5-lipoxygenase (5-LOX) pathway
and is well-known as a biologic mediator in several chronic
inflammatory diseases as asthma, psoriasis, rheumatoid arthritis,
and inflammatory bowel disease [13,14]. As in other cancers,
cyclooxygenase-2 (COX-2) plays a role in the growth and spread
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of pancreatic cancers [15]. However, the 5-LOX pathway
seems to play an evenmore important role in pancreatic cancer
growth and development [15,16]. The LTB4 antagonist activity
of LY293111 was evaluated previously in clinical testing for
inflammatory conditions [17–20]. Although it was found to be
safe and well-tolerated, the development of the drug for
inflammatory conditions was discontinued [21].
However, to bring new treatments from the laboratory into
the clinic, adequate in vivo studies are required. The subcu-
taneous xenograft model for pancreatic cancer is limited
because the tumor is growing in an unusual environment
(subcutaneous) without high concentrations of important
growth factors, such as insulin. There are also differences in
tumor biology and morphology in this xenotopic site [22,23].
Therefore, in the current study, we used an orthotopic tumor
model in athymic mice to determine the effectiveness of
LY293111 alone and in combination with gemcitabine in
vivo. This model employs S2-013 cells with stable transfec-
tion of green fluorescent protein (GFP). Because the tumors
grow in their natural tissue environment, they develop me-
tastases and mimic the clinical course of pancreatic cancer
with obstruction of the duodenum and bile duct, and induction
of cachexia. Moreover, the S2-013 human pancreatic cancer
cell line was chosen among several others because of its
metastatic potential and high aggressiveness to challenge
the effectiveness of LY293111. The fluorescent model en-
ables dynamic monitoring of tumor growth and metastases
under different therapeutic strategies [24,25].
Materials and Methods
Cell Lines and Cell Cultures
S2-013, a subclone of SUIT-2, is a well-differentiated cell
line derived from a liver metastasis of human pancreatic
adenocarcinoma [26–28]. These cells were stably trans-
fected with enhanced GFP and provided by Dr. M.A. Holling-
sworth (Eppley Cancer Institute, Omaha, NE). The cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM),
supplemented with 10% fetal bovine serum, 100 U/ml peni-
cillin, 100 mg/ml streptomycin, and 0.25 mg/ml amphotericin B
(Cellgro; Mediatech, Inc., Herndon, VA). S2-013 tumor cells
were harvested from 90% confluent cultures grown in T75
flasks (Corning, Inc., Corning, NY). The tumor cells were
trypsinized, then the cell number was counted using a Guava
Personal Cytometer (Guava Technologies, Inc., Hayward,
CA) and resuspended in DMEM.
Animals and Surgical Orthotopic Tumor Cell
Implantation (SOI)
Thirty-two 6- to 8-week–old female athymic nude (nu/nu)
mice purchased from the National Cancer Institute were
used in this study. The mice were housed in a two-way
barrier facility in microisolator cages on static racks, fed with
autoclaved laboratory rodent food pellets and acclimatized
to the facility for 1 week before SOI. Animal weight was
recorded everyday. Their use in this study was approved by
the Institutional Animals Care and Use Committee and all
procedures were conducted in accordance with the regula-
tions and standards of the National Institutes of Health.
Mice were anesthesized intraperitoneally with 0.05 ml of
a mixture of 0.4 ml of ketamine (Fort Dodge Animal Health,
Fort Dodge, IO), 0.1 ml of xylazine (Phoenix Scientific, Inc.,
St. Joseph, MO), and 0.5 ml of NaCl. The abdomen was
sterilized with alcohol pads and a 0.5-cm midline incision
was performed. The abdominal wall was wrapped with
wet gauze. After pulling the stomach on the surface, the
pancreas was then carefully exposed and tumor cells (5 
105 in 10 ml of DMEM) were injected into the duodenal lobe
using a monoject 200 27-gauge1/2 in. polypropylene hub
hypodermic needle (Kendall, Mansfield, MA) and a 50-ml
glass syringe (Hamilton Company, Reno, NV). The needle
was carefully withdrawn and the injection sealed with a dry
cotton tip. The successful injection was confirmed using a
stereo fluorescence microscope. After the stomach and pan-
creas were returned to the peritoneal cavity, the incision was
closed in two layers with vicryl-coated Rapide sutures 4-0
(Ethicon, Inc., Somerville, NJ). Once the mice were ambula-
tory, they were placed in the animal barrier facility. The mice
were kept in a sterile environment throughout the procedure.
Therapy
One day after SOI, the mice were randomized into four
groups: Group I (Control) received daily oral doses of the
vehicle, DMSO (1/2 ml/g per day); Group II (LY293111)
received daily oral doses of LY293111 (250 mg/kg per day,
dissolved in DMSO and administered 1/2 ml/g per day);
Group III (Gemcitabine) received daily oral dosages of
DMSO (1/2 ml/g per day) and intraperitoneal injections of
gemcitabine (60 mg/kg per dose dissolved in PBS and ad-
ministered 2 ml/g per day) on days 4, 7, 10, and 13 after SOI;
and Group IV (LY293111 + gemcitabine) received daily oral
dosages of LY293111 (250 mg/kg per day) and intraperito-
neal injections of gemcitabine (60 mg/kg per dose) on days
4, 7, 10, and 13 after SOI. LY293111 and gemcitabine were
provided by Eli Lilly (Indianapolis, IN). Eight mice were as-
signed to each group and treated for 4 weeks, at which time
the experiment was terminated and animals were euthanized.
Surgical Follow-Up Procedures
The mice underwent follow-up procedures 2 weeks
after SOI. Mice were anesthesized with the same mixture
of ketamine, xylazine, and NaCl. A horizontal arc-shaped
incision was made through the skin and connective tissue
was bluntly separated from the peritoneum with a curved
scissors to free the skin flap (reversible skin flap) [29]. Digital
pictures of tumors were taken with and without fluorescence,
and staging of peritoneal tumors, pancreatic tumors, lymph
node metastases, liver metastases, and ascites was per-
formed and recorded according to our TMPN scoring system
(Table 1, Figure 1). The scores from each category were
multiplied with each other because patterns in medicine
follow multiplicative, rather than additive, rules. The incision
was closed with vicryl-coated Rapide 4-0 sutures. Follow-up
surgeries were performed in the second, third, and fourth
weeks after SOI.
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After the last follow-up, mice were euthanized using a
higher dose of the same mixture of ketamine, xylazine, and
NaCl (0.1 ml). A midline skin incision was made from the
area just above the bladder to the clavicles and the connec-
tive tissue was separated. After staging and imaging using
the stereo fluorescence microscope, ascites was collected. If
no ascites was accessible by abdominal puncture, a brushing
of the peritoneal cavity was taken with a cotton-tipped appli-
cator (Henry Schein, Inc., Melville, NY) and smeared onto a
microscope slide. Staging and imaging were performed be-
fore and after opening the peritoneum and thoracic cavity.
From eachmouse, peritoneal tumor, pancreatic tumor, lymph
node, liver, and lung tissues were harvested and fixed in 4%
formaldehyde for 12 hours. Prior to fixation, peritoneal and
pancreatic tumors were weighed andmeasured in length and
width and the tumor volume calculated as follows: volume =
(length) (width) (length+width/2)0.526. The whole pan-
creas was collected en bloc with tumor, 5 mm of the proximal
duodenum and the whole stomach. The stomach was cut
and emptied, and the entire cluster of tissues was weighed,
whereas only the pancreatic tumor was measured. Liver,
lung, and thoracic lymph node tissues were further checked
for any metastases with the stereo fluorescence microscope
at higher magnification and photographed. After 12 hours of
tissue fixation, 4% formaldehyde was replaced with 70%
ethanol, and tissues were then paraffin-embedded according
to histology standard protocols.
Imaging
Images were taken with a Nikon stereoscopic zoom
microscope model SMZ1500 equipped with a DC10NN
high-resolution video camera and a 100-W mercury lamp
(Nikon Instruments, Inc., Melville, NY). A tungsten halogen
lamp (Schott-Fostec, LLC, Auburn, NY) with a variable
powered output of 150 W of light was also used. Selective
excitation of GFP was produced through a HQ480/40 band-
pass filter and 495 dichroic mirror. Emitted fluorescence was
collected through a longpass 500 filter. Images were pro-
cessed and analyzed using Image Pro Plus 4.5 software
(Media Cybernetics, Silver Spring, MD).
Histology
Hematoxylin and eosin (H&E) staining with Gill’s Hema-
toxylin (Fisher Scientific, Fair Lawn, NJ) and Eosin Y (Ameri-
can Master Tech Scientific, Inc., Lodi, CA), each for 5 minutes,
was used for routine staining of 4-mm tissue sections. Histo-
logic evaluation was performed under light microscopy. Sec-
tions were mounted with Permount (Fisher Scientific).
Statistical Analysis
Tumor staging scores, tumor weight, and tumor volume
were compared using ANOVA as a parametric test and
Kruskal-Wallis ANOVA on ranks as a nonparametric test.
Student-Newman-Keuls was used as post-hoc test. Fisher’s
exact test was used to compare differences in the frequency
of metastases. Data from all 32 animals were statistically
analyzed and differences were considered as statistically
significant when P < .05. Graphs were created using the
GraphPad Prism Software.
Results
Tumor Model S2-013 GFP
S2-013 is a highly aggressive, invasive, and spontane-
ously metastasizing human pancreatic cancer cell line. Using
our injection technique, we were able to target injection of
the tumor cells into a discrete region of the duodenal lobe of
the pancreas without leakage. Success of each injection was
confirmed by stereo fluorescence microscopy (Figure 1).
Untreated animals develop an end-stage disease within
4 weeks after SOI and present with a primary tumor invading
neighboring tissues; obstructing the duodenum and bile
duct; metastasizing to the lymph nodes, liver, and lung;
and causing peritoneal carcinomatosis with malignant as-
cites and cachexia (Figure 1). Therefore, injecting S2-013
GFP tumor cells into the duodenal lobe of the pancreas
mimics the clinical features of human pancreatic adeno-
carcinoma. The technical approach was very reliable and
tumor formation was seen in all animals. The GFP expres-
sion of the cells enabled us to dynamically monitor primary
tumor growth and the development of metastases, and
therefore to compare disease stages under different thera-
peutic strategies (Figure 1).
Body Weight
Body weights between the four groups were not sig-
nificantly different throughout the experiment. It should be
noted that the measured body weights at the end of the
Table 1. TMPN Classification and Scoring System.
Staging and Scoring System
Stage Description Score
Primary tumor
T0 No tumor 1
T1 Small tumor (tumor d < 7 mm) 2
T2 Large tumor without infiltration (tumor d > 7 mm) 3
T3 Large tumor with infiltration but still visible margins 4
T4 Diffuse and infiltrating tumor 5
Organ metastases
M0 No liver or lung metastases 1
M1Li Liver metastases 5
M1Lu Lung metastases 5
M1 Liver and lung metastases 10
Peritoneal metastases
P0 No peritoneal metastases 1
P1 Less than five peritoneal metastases or one with d < 7 mm 3
P2 More than five peritoneal metastases or one with d > 7 mm 4
P3 Malignant ascites 5
Lymph node metastases
N0 No lymph node metastases 1
N1 Peripancreatic lymph node metastases 3
N2 Regional lymph node metastases (e.g., mesenteric, Virchow) 5
Scores for the primary tumor (T), organ metastases (M), peritoneal
metastases (P), and lymph node metastases (N) were multiplied to calculate
the total tumor score for each animal.
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experiment do not fully reflect the nutritional state of the
animals because of different tumor loads and volumes of
ascites. After correcting body weights for these values, we
observed a 1.2-g increase in gemcitabine-treated animals
between the beginning and end of the experiment. The
untreated mice as well as animals under treatment with
LY293111 alone lost between 1.4 or 2 g of body weight,
whereas weights of mice receiving the combined therapy of
gemcitabine and LY293111 remained stable.
Tumor Staging
According to the TNM classification, we developed a
scoring system that was used to perform a weekly staging
of the disease. Tumor staging systems have not been used
in previous orthotopic tumor models, so effectiveness of
novel anticancer therapeutics was rather descriptive and
observer-dependent. The tumor scores showed significant
differences between treated groups and the control group in
all follow-ups, with the highest score in control animals and
the lowest score in animals treated with the combination of
LY293111 and gemcitabine (Figure 2). LY293111 alone was
the least effective treatment (Figure 2). However, the tumor
score was lower compared to controls, a difference that
was significant in the fourth week after SOI (Figure 2).
Animals treated with gemcitabine alone or in combination
with LY293111 showed significantly lower tumor scores than
the control and LY293111 groups at all follow-ups (Figure 2).
Moreover, the combined treatment of gemcitabine and
LY293111 proved to be significantly better than gemcitabine
alone with regard to tumor scores at weeks 3 and 4 after SOI
(Figure 2), suggesting a benefit from combining LY293111
with gemcitabine.
Duodenal obstruction was not included in the scoring
system. The decision as to whether or not the duodenum is
obstructed was made when a tumor was strangulating the
pylorus or duodenum and the stomach was distended. Four
of eight animals in the control group, three of eight in the
LY293111 group, and one of eight in the gemcitabine group
showed duodenal obstruction, whereas none of the animals
treated with LY293111 and gemcitabine suffered from this
clinical feature.
Tumor Weight and Volume
The measurements of tumor weight and calculations of
tumor volume for the primary tumor in the pancreas and
peritoneal metastases revealed similar results and the
same pattern of therapeutic effectiveness as was obtained
with the tumor scores. All three treated groups had a sig-
nificantly lower tumor weight and volume of the primary
tumor compared to control, whereas no significant differ-
ences between these different treatment options were ob-
served (Figure 3). However, LY293111 alone was again the
least effective therapy and LY293111 + gemcitabine
appeared to be most effective (Figure 3). Because of highly
invasive tumors, particularly in the untreated animals, it was
not possible to completely separate the tumor from adjacent
organs. The weight of a whole tissue cluster consisting of the
pancreas, empty stomach, and 5 mm of proximal duodenum
was measured in all 32 animals. Thus, the primary ‘‘tumor
weight’’ in all groups includes the weight of these adjacent
tissues. Tumor weights and volumes of peritoneal metasta-
ses were also markedly decreased, particularly following
treatment with gemcitabine alone or in combination with
LY293111; however, this did not reach statistical significance
(Figure 4).
Hepatic and Lung Metastases
Five of eight untreated animals developed liver and lung
metastases, whereas one mouse showed only lung metas-
tases and two others showed no metastases (Figure 5).
Treatment with LY293111 or gemcitabine decreased the in-
cidence of lung metastases to three in each group, whereas
only one animal in the LY293111 + gemcitabine group
developed lung micrometastases (Figure 5). It should be
mentioned that the technical problem of peritoneal leakage
of tumor cells during SOI was recorded in this animal; how-
ever, it was decided that it should not be excluded from
the study. Even more interesting is that only two animals
treated with LY293111 had liver metastases, whereas gem-
citabine alone or in combination with LY293111 completely
eliminated the occurrence of liver metastases (Figure 5).
Overall, except in one animal where we recorded technical
problems in SOI, only the combined therapy with LY293111
and gemcitabine seems to be able to completely prevent the
development of liver and lung metastases (Figure 5). How-
ever, statistical significance was reached only at a 10% a
level (P = .0844).
Histology
Histologic examination of primary tumor, liver, lung, and
lymphatic tissues from all animals was carried out by light
microscopy at the end of the experiment. The pancreatic
tumors showed the morphology of a poorly differentiated
pancreatic adenocarcinoma, invading peripancreatic lymph
nodes and neighboring organs. The metastases in the liver,
lung, and lymph nodes observed by stereo fluorescence
microscopy were confirmed histologically. Liver metastases
appeared to develop from migration of tumor cells by blood
and lymphatic vessels into the liver because tumor cells were
seen in the lumens of hepatic blood and lymphatic vessels
(Figure 1).
Discussion
Gemcitabine is the standard palliative treatment in unresect-
able pancreatic cancers and is the usual therapeutic base-
line in adjuvant and neoadjuvant clinical trials, attempting to
improve on the desperate situation of pancreatic cancer
patients. Pancreatologists all over the world are looking for
a beneficial drug to combine with gemcitabine. Taking all of
the data together, the combined therapy of gemcitabine and
LY293111 potently inhibits the growth and metastases of this
very rapidly growing and aggressive pancreatic adenocarci-
noma. Sun et al. [30] reported that gemcitabine at a dose of
300 mg/kg per dose injected three times could not inhibit the
development of lung metastases compared to untreated
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Figure 1. A summary of optical images is shown, captured by a digital video camera–equipped stereo fluorescence microscope and light microscope. Four weeks
after SOI: (1a) untreated mouse with cachexia and ascites; (1b) normal looking-mouse treated with LY293111 and gemcitabine; (2) confirmation of SOI of S2-013
GFP cells into the duodenal lobe of the pancreas by (a) light and (b) fluorescent microscopy (7.5); (3) growth of a primary tumor in (a) the second, (b) third, and
(c + d) fourth weeks after SOI in an untreated control animal (3c + d: eight pictures with 7.5 magnification capture the tumor; p = pylorus, d = duodenum); (4)
primary tumor growth in (a) the second, (b) third, and (c + d) fourth weeks after SOI from an animal treated with LY293111 and gemcitabine (7.5); (5a + b) grossly
distended bile duct in a control mouse and (6a + b) normal bile duct without tumor in an LY293111 and gemcitabine– treated mouse (7.5; PV = papilla vateri); (7a)
mesenteric lymph node metastases in a control animal and (7b) normal mesentery in a LY293111 and gemcitabine– treated animal (7.5); (8) intrathoracic lymph
node metastasis in a control animal visualized (a) through the chest wall (7.5) and (b) extirpated on gauze (20); (9a + b) peripancreatic lymph node metastases
(7.5); (10) liver metastasis (7.5) and (11) lung micrometastases in a control animal (20); (12) malignant ascites in a control animal; (13) primary pancreatic
tumor with desmoplastic reaction and duct-like tumor structures; liver metastases with (14) intravascular and (15) intralymphatic tumor cells; and (16) lung
micrometastasis (12–16, all from a control animal, 200; 13–16, H&E–stained).
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controls. However, in our tumor model, gemcitabine at a
dose of 60 mg/kg per dose injected four times to some extent
inhibited the occurrence of lung metastases while completely
eliminating liver metastases. The efficacy of gemcitabine in
preventing metastases was markedly improved in combi-
nation with LY293111. Nevertheless, it should be mentioned
that we started treatment with LY293111 from the first, and
gemcitabine from the fourth, day after SOI because of this
highly aggressive S2-013 tumor model, with rapid cancer
development in all animals used. However, the treatment
strategy of gemcitabine and LY293111 significantly delayed
the progression of human pancreatic cancer in this ortho-
topic nude mouse tumor model. Moreover, LY293111 can be
administered orally and showed no apparent toxicity; there-
fore, patient compliance could be expected. Body weight did
not significantly differ between the experimental groups at
any time during the experiment. It might be anticipated that
the cachectic animals in the control group would have lost
weight during the latter stages of the disease; however, the
substantial tumor burden and volume of ascites substantially
contributed to total body weight in this group. Furthermore,
an increase in body weight might also have been expected in
the groups treated with LY293111 compared with their
respective controls, but this was not seen. Because of the
problem with measuring body weight in fully ambulatory
animals, the measurement is inherently noisy. If a small
effect of LY293111 on food intake or body weight gain had
occurred, it was not revealed in the present study. The
condition of the animals with hepatic and lung metastases
is very much worse than that of animals with only lymph node
metastases. Indeed, the experiments were terminated be-
cause of the poor condition of the control animals, and this
was part of the institutional animal care protocol.
Thus, combined therapy of gemcitabine + LY293111
could be a promising approach in treating pancreatic ade-
nocarcinoma. This therapeutic strategy should be consid-
ered for neoadjuvant, adjuvant, and palliative clinical trials
in pancreatic cancer patients because there is a significant
Figure 2. Tumor scores (mean ± SEM) in the second, third, and fourth weeks
after SOI of S2-013 GFP human pancreatic cancer cells are shown. Groups
include control; LY293111 (LY); (250 mg/kg per day); gemcitabine (Gem)
(60 mg/kg per dose); and combined LY293111 and gemcitabine (LY + Gem)
therapy. All P values are shown in Table 2.
Table 2. Summary of Statistical Data.
Comparison ANOVA Kruskal Fisher’s Normality Test
Pancreatic tumor volume P = .004 P = .007 Failed
C versus LY P = .056 P < .05
C versus Gem P = .006 P < .05
C versus LY&Gem P = .006 P < .05
Peritoneal tumor volume P = .023 P = .114 Failed
C versus Gem P = .039
C versus LY&Gem P = .026
Pancreatic tumor weight P = .001 P = .004 Passed
C versus LY P = .016 P < .05
C versus Gem P = .005 P < .05
C versus LY&Gem P = .001 P < .05
Peritoneal tumor weight P = .038 P = .058 Passed
Staging second week P = .022 P = .019 Failed
C versus LY P = .088
C versus Gem P = .029 P < .05
C versus LY&Gem P = .024 P < .05
LY versus Gem P < .05
LY versus LY&Gem P < .05
Staging third week P = .043 P = .01 Failed
C versus Gem P < .05
C versus LY&Gem P = .044 P < .05
LY versus Gem P < .05
LY versus LY&Gem P < .05
Gem versus LY&Gem P < .05
Staging fourth week P < .001 P = .007 Passed
C versus LY P = .002 P < .05
C versus Gem P = .001 P < .05
C versus LY&Gem P < .001 P < .05
LY versus LY&Gem P < .05
Gem versus LY&Gem P < .05
Total metastases P = .084
Liver metastases P = .006
Lung metastases P = .122
P values for comparisons.
ANOVA as parametric and Kruskal-Wallis as nonparametric test.
C = control; LY = LY293111; Gem = gemcitabine; LY&Gem=LY293111 and
gemcitabine.
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beneficial effect of adding LY293111 to gemcitabine treat-
ment. This benefit was seen even though gemcitabine alone
is very effective in this model. LY293111 seems to have an
additional, rather than a synergistic, effect to gemcitabine. In
the present study, we do not claim tumor regression because
this is particularly difficult in pancreatic cancer because of the
marked desmoplastic reaction. Even gemcitabine does not
induce tumor regression in most patients with this disease.
According to the present study, LY293111 may be particu-
larly valuable for patients undergoing potentially curative
surgery, but may also be useful for patients desperately
looking for better palliative treatment strategies than gemci-
tabine alone. The high compliance of cancer patients can be
assumed to be due to oral availability and minor side effects.
The molecular mechanism by which LY293111 inhibits
tumor growth is a matter of debate. In addition to its originally
described inhibitory effects on the LTB4 receptor, LY293111
has also been shown to be an agonist for the peroxisome
proliferator-activated receptor g (PPARg) and also a weak
5-LOX inhibitor. All three functions have been linked to
the inhibition of cancer cell growth. It is possible that the
anticancer effects of LY293111 involve all of these and per-
haps even other unrecognized pathways, but this may make
the drug even more useful in the clinic. LY293111 will, of
course, exhibit some anti-inflammatory properties, but this
is also likely to be valuable in the clinic.
The current study also demonstrates the importance of an
adequate tumor model for testing new treatment options. It
has been shown by Hoffman [31] that the orthotopic meta-
static mouse model is a clinically relevant and appropriate
tumor model for the evaluation of new anticancer drugs and,
therefore, provides a bridge to clinical trials. We modified the
model of SOI by injecting tumor cells into the duodenal part
of the pancreas. With this modification, cancer development
mimics the clinical course of pancreatic cancer in humans,
including duodenal and bile duct obstruction. Moreover, the
Figure 3. Primary pancreatic tumor weights and volumes (mean ± SEM)
4 weeks after SOI of S2-013 GFP human pancreatic cancer cells. Groups
include control; LY293111 (LY); (250 mg/kg per day); gemcitabine (Gem)
(60 mg/kg per dose); and combined LY293111 and gemcitabine (LY + Gem)
therapy. All P values are shown in Table 2.
Figure 4. Peritoneal tumor weights and volumes (mean ± SEM) 4 weeks after
SOI of S2-013 GFP human pancreatic cancer cells. Groups include control;
LY293111 (LY); (250 mg/kg per day); gemcitabine (Gem) (60 mg/kg per
dose); and combined LY293111 and gemcitabine (LY + Gem) therapy. All
P values are shown in Table 2.
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human pancreatic cancer cell line, S2-013, was chosen be-
cause of its aggressiveness and spontaneous development
of liver, lung, and lymph node metastases. However, the
greatest advantage was provided by the stable expression of
GFP and the application of the reversible skin flap, enabling
us to study the course of tumor progression and develop-
ment of metastases dynamically over time [29,25]. A scoring
system was introduced in an attempt to improve on previous
approaches with orthotopic models, which has been used to
describe the presence or absence of metastases. The scor-
ing systemwas prospectively developed by the investigators,
and scoring was undertaken in a blinded fashion to prevent
investigator bias. It should be noted that this scoring system
has not been validated with regard to animal survival. Fur-
thermore, we have no information on how it may parallel
the TNM score in humans or future clinical experiences with
this drug. Establishing the human TNM score was a long-
term and slowly evolving process, involving multiple centers
in several countries. If others adopt our scoring system or
something similar, then this will perhaps provide the oppor-
tunity to develop and improve this scoring system.
In conclusion, LY293111 improves the efficacy of
gemcitabine in an orthotopic model of human pancreatic
adenocarcinoma.
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